Sironax' lead RIPK1 drug, SIR0365, has completed two phase 1b studies including one looking at its potential as a treatment for severe hyperinflammation associated with COVID-19 infections, while ...

When TBK1 is lost or mutated, it fails to perform its protective role, allowing two major cell death pathways, RIPK1 and NLRP3, to become overactive. This overactivity leads to excessive cell ...